Edition:
United States

Oasmia Pharmaceutical AB (OASM.ST)

OASM.ST on Stockholm Stock Exchange

2.48SEK
20 Oct 2017
Change (% chg)

-0.10kr (-3.88%)
Prev Close
2.58kr
Open
2.59kr
Day's High
2.59kr
Day's Low
2.46kr
Volume
354,577
Avg. Vol
593,830
52-wk High
10.56kr
52-wk Low
2.46kr

Latest Key Developments (Source: Significant Developments)

Oasmia Q1 operating loss lower
Friday, 1 Sep 2017 02:22am EDT 

Sept 1 (Reuters) - Oasmia Pharmaceutical Ab :Says Q1 operating loss was TSEK 28,421 compared to TSEK 32,343 in Q1 previous year.Consolidated net sales amounted to TSEK 20 compared to TSEK 36 in the first quarter previous year.  Full Article

Oasmia Pharmaceutical says through rights issue, its share capital up by 5 mln SEK to 17.6 mln SEK
Friday, 7 Jul 2017 04:05pm EDT 

July 7 (Reuters) - Oasmia Pharmaceutical Ab :Says through rights issue, Oasmia's share capital increases by sek 5 million to sek 17.6 million.New shares subscribed for by exercise of preferential rights are expected to be admitted to trading on nasdaq stockholm on July 27, 2017.New shares subscribed for without preferential rights are expected to be admitted to trading around August 2, 2017.  Full Article

Oasmia enters into marketing, distribution agreement concerning Russia, other markets
Wednesday, 14 Jun 2017 07:00am EDT 

June 14 (Reuters) - Oasmia Pharmaceutical AB ::Oasmia Pharmaceutical enters into new exclusive marketing and distribution agreement concerning Russia and other CIS markets.Says terms in agreement are similar to previous agreement for region.Oasmia Pharmaceutical - Oasmia and Hetero Group also signed a letter of intent regarding India and South America, which will be negotiated separately.  Full Article

Oasmia to carry out preferential rights issue of around 164 mln SEK
Monday, 12 Jun 2017 02:30am EDT 

June 12 (Reuters) - Oasmia Pharmaceutical AB (Publ) :The Board Of Directors Resolves Upon A Rights Issue Of Approximately 163.9 MSEK.Says subscription price in rights issue is 3.25 SEK per new share.Says rights issue is 100 per cent covered by subscription and guarantee commitments.Shareholders in Oasmia have preferential rights to subscribe for two (2) new shares for every five (5) existing shares, i.e. a subscription ratio of 2:5.  Full Article

Oasmia says to spin-off veterinary assets valued at $75-80 mln
Wednesday, 10 May 2017 02:45am EDT 

May 10 (Reuters) - Oasmia Pharmaceutical AB :Says to spin-off veterinary assets.Says Based on an independent valuation by one of the big four accounting firms, the fair market value of the registered intellectual property relating to Oasmia’s animal oncology products, Paccal Vet and Doxophos Vet, is assessed in the range of USD 75 - 80 million.Says has appointed New York based advisors to evaluate potential financial and strategic alternatives for veterinary business, including private placement, public offering of common stock in U.S. Subsidiary and strategic collaborations within veterinary field.  Full Article

Karo Pharma says have sold Oasmia shares consisting "down payment" for KB 9520 project
Friday, 3 Mar 2017 04:00am EST 

Karo Pharma AB : Says board decided on Feb. 2 to sell Oasmia shares consisting "down payment" for KB 9520 project . Says shares are sold and the board will propose the AGM on May 11 to distribute the value of the shares to its shareholders .Says chairman Anders Lonner was not part of decision as he was an insider in Oasmia.  Full Article

Oasmia Q3 operating loss deepens
Friday, 3 Mar 2017 02:15am EST 

Oasmia Pharmaceutical AB : Q3 consolidated net sales amounted to TSEK 36 compared to TSEK 6,043 in Q3 previous year . Q3 operating loss was TSEK 34,861 compared to a loss of TSEK 23,245 in Q3 previous year . Says efficiency programme initiated at end of 2016 is proceeding according to plan .Says regarding further financing of operation until company can generate revenues in form of sales, royalties, milestones etc. And thereby becomes fully financed on its own merits, there are several alternative solutions.  Full Article

Oasmia issues comments on chairman resignation
Wednesday, 1 Mar 2017 02:30am EST 

Oasmia Pharmaceutical AB (Publ) : Oasmia makes clarification regarding chairman Anders Lonner's withdrawal from Board Of Directors . Says withdrawal must be viewed against backdrop that Oasmia in no way has been able to accept Mr Lonner's actions and demands he has made after he was elected chairman .Lonner was elected chairman just over 3 months ago.  Full Article

Oasmia Pharma says to move veterinary assets to United States
Monday, 23 Jan 2017 02:40am EST 

Oasmia Pharmaceutical : Says announces strategic move to bolster efforts for its Veterinary Division . Says plans to move all of company's veterinary assets including Paccal Vet and Doxophos Vet, to United States for further development and commercialization efforts . Says key objective within veterinary medicine is to successfully transition the products on a broader scale to a larger number of veterinary clinics . Clinical program with Doxophos Vet is ongoing, with the expectation to communicate the results from a proof of concept study during the spring of 2017 . Says anticipates that changing the treatment regime of Paccal Vet-CA1 by lowering the dose to reduce side effects and improve comfort for companion animals, the product will become far more attractive to veterinarians and pet owners. . Says in order to achieve this goal, the Company has withdrawn its current label which is conditionally approved and plan to initiate a new study confirming the changed dosing regimen. .These strategic changes are expected to be implemented during 2017.  Full Article

Oasmia Pharmaceutical Q1 loss per share SEK 0.34
Friday, 2 Sep 2016 09:36am EDT 

Oasmia Pharmaceutical AB:Q1 loss per share SEK 0.34.  Full Article

BRIEF-Oasmia CFO resigns

* Oasmia Pharmaceutical Ab Announces Resignation Of Its Chief Financial Officer